News

Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, and BDD Pharma, a drug delivery company specializing in modified and controlled release oral formulations, announce dosing of first subject in a Phase 1 pharmacoscintigraphic study in healthy volunteers. The study will evaluate a novel delayed-release, dual pulse levodopa / carbidopa tablet (CP-012), […]

Abzu® and Contera Pharma expand their strategic partnership to add drug-target identification to their seminal RNA- and siRNAs therapeutic design platform. Contera Pharma is a Danish biotech company -developing innovative small-molecule and RNA-based therapeutics to address neurological disorders. Their unique R&D model integrates their team of experienced neuroscience drug hunters with cutting-edge technology, like Abzu’s […]

Cambridge UK, and Copenhagen, Denmark, 27 September 2022 – Vernalis Research (“Vernalis”), a fully owned subsidiary of HitGen Inc., and Contera Pharma A/S (“Contera”) are pleased to announce a strategic drug discovery collaboration on an undisclosed target. Under the terms of the agreement, Vernalis and Contera will use their respective expertise in fragment and structure-based drug design […]

Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, has entered into collaboration with BDD Pharma, a drug delivery company specializing in modified and controlled release oral formulations, to begin the development of a novel formulation of levodopa / carbidopa (CP-012) to specifically treat Parkinson´s disease (PD) patients suffering from nocturnal or […]

Abzu, an applied research startup who has developed a pioneering explainable artificial intelligence (xAI), and Contera Pharma, a biotech company developing innovative therapies to treat neurological disorders, are partnering to design nucleic acid-based medicines. Abzu will collaborate exclusively with Contera Pharma on two undisclosed targets within rare neurological diseases. According to recent research in European […]

Contera Pharma, a subsidiary of Bukwang, announced that it elected Dr. Thomas Sager as CEO while further expanding the executive management team to include representatives for Business Development and R&D Chief Executive Officer; Thomas Sager, PhD. Chief Business Officer; Anders Brandt Elvang, PhD. Chief Science Officer; Kenneth Vielsted Christensen, PhD. Thomas Sager, received his PhD […]